{
    "organizations": [],
    "uuid": "c53d6cb01853208c78ad2f200bd16d733f1c2870",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-acorda-therapeutics-reports-q1-non/brief-acorda-therapeutics-reports-q1-non-gaap-earnings-per-share-of-0-14-idUSASC09YVR",
    "ord_in_thread": 0,
    "title": "BRIEF-Acorda Therapeutics Reports Q1 Non-GAAP Earnings Per Share Of $0.14",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 2 (Reuters) - Acorda Therapeutics Inc:\n* ACORDA PROVIDES FINANCIAL AND PIPELINE UPDATE FOR FIRST QUARTER 2018\n* Q1 NON-GAAP EARNINGS PER SHARE $0.14\n* Q1 REVENUE $103 MILLION * Q1 EARNINGS PER SHARE VIEW $0.47 — THOMSON REUTERS I/B/E/S\n* Q1 REVENUE VIEW $129.9 MILLION — THOMSON REUTERS I/B/E/S * EXPECTS TO END 2018 WITH A PROJECTED YEAR-END CASH BALANCE IN EXCESS OF $300 MILLION\n* FDA ACCEPTED INBRIJA(LEVODOPA INHALATION POWDER) NDA; PDUFA DATE OCTOBER 5, 2018\n* ACORDA THERAPEUTICS SAYS EXPECTS TO MAINTAIN EXCLUSIVITY OF AMPYRA AT LEAST THROUGH JULY 30, 2018\n* ACORDA THERAPEUTICS - 2018 RESEARCH AND DEVELOPMENT EXPENSES EXPECTED TO BE $100 MILLION TO $110 MILLION AND INCLUDE MANUFACTURING EXPENSES ASSOCIATED WITH INBRIJA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-02T18:08:00.000+03:00",
    "crawled": "2018-05-03T12:07:29.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "acorda",
        "therapeutic",
        "inc",
        "acorda",
        "provides",
        "financial",
        "pipeline",
        "update",
        "first",
        "quarter",
        "q1",
        "earnings",
        "per",
        "share",
        "q1",
        "revenue",
        "million",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "q1",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "expects",
        "end",
        "projected",
        "cash",
        "balance",
        "excess",
        "million",
        "fda",
        "accepted",
        "inbrija",
        "levodopa",
        "inhalation",
        "powder",
        "nda",
        "pdufa",
        "date",
        "october",
        "acorda",
        "therapeutic",
        "say",
        "expects",
        "maintain",
        "exclusivity",
        "ampyra",
        "least",
        "july",
        "acorda",
        "therapeutic",
        "research",
        "development",
        "expense",
        "expected",
        "million",
        "million",
        "include",
        "manufacturing",
        "expense",
        "associated",
        "inbrija",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}